Logo image of IDYA

IDEAYA BIOSCIENCES INC (IDYA) Stock Fundamental Analysis

NASDAQ:IDYA - Nasdaq - US45166A1025 - Common Stock - Currency: USD

21.85  +0.12 (+0.55%)

After market: 21.85 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to IDYA. IDYA was compared to 572 industry peers in the Biotechnology industry. While IDYA has a great health rating, there are worries on its profitability. IDYA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IDYA has reported negative net income.
In the past year IDYA has reported a negative cash flow from operations.
In the past 5 years IDYA always reported negative net income.
IDYA had negative operating cash flow in 4 of the past 5 years.
IDYA Yearly Net Income VS EBIT VS OCF VS FCFIDYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

IDYA's Return On Assets of -14.37% is amongst the best of the industry. IDYA outperforms 83.66% of its industry peers.
IDYA has a Return On Equity of -15.09%. This is amongst the best in the industry. IDYA outperforms 88.99% of its industry peers.
Industry RankSector Rank
ROA -14.37%
ROE -15.09%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IDYA Yearly ROA, ROE, ROICIDYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

IDYA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDYA Yearly Profit, Operating, Gross MarginsIDYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

IDYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for IDYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IDYA Yearly Shares OutstandingIDYA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
IDYA Yearly Total Debt VS Total AssetsIDYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 18.77 indicates that IDYA is not in any danger for bankruptcy at the moment.
IDYA has a better Altman-Z score (18.77) than 92.90% of its industry peers.
There is no outstanding debt for IDYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.77
ROIC/WACCN/A
WACC9.44%
IDYA Yearly LT Debt VS Equity VS FCFIDYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

IDYA has a Current Ratio of 22.93. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
IDYA has a Current ratio of 22.93. This is amongst the best in the industry. IDYA outperforms 95.38% of its industry peers.
A Quick Ratio of 22.93 indicates that IDYA has no problem at all paying its short term obligations.
IDYA's Quick ratio of 22.93 is amongst the best of the industry. IDYA outperforms 95.38% of its industry peers.
Industry RankSector Rank
Current Ratio 22.93
Quick Ratio 22.93
IDYA Yearly Current Assets VS Current LiabilitesIDYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

IDYA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.51%.
The Revenue for IDYA has decreased by -70.06% in the past year. This is quite bad
Measured over the past years, IDYA shows a very negative growth in Revenue. The Revenue has been decreasing by -36.96% on average per year.
EPS 1Y (TTM)-67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.54%
Revenue 1Y (TTM)-70.06%
Revenue growth 3Y-36.96%
Revenue growth 5YN/A
Sales Q2Q%78.43%

3.2 Future

IDYA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.92% yearly.
The Revenue is expected to grow by 177.47% on average over the next years. This is a very strong growth
EPS Next Y11.16%
EPS Next 2Y5.46%
EPS Next 3Y6.92%
EPS Next 5Y21.92%
Revenue Next Year226.3%
Revenue Next 2Y233.35%
Revenue Next 3Y235.16%
Revenue Next 5Y177.47%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IDYA Yearly Revenue VS EstimatesIDYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IDYA Yearly EPS VS EstimatesIDYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IDYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IDYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IDYA Price Earnings VS Forward Price EarningsIDYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDYA Per share dataIDYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.46%
EPS Next 3Y6.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IDYA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDEAYA BIOSCIENCES INC

NASDAQ:IDYA (2/21/2025, 8:27:40 PM)

After market: 21.85 0 (0%)

21.85

+0.12 (+0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)05-05 2025-05-05
Inst Owners109.03%
Inst Owner Change-93.26%
Ins Owners0.91%
Ins Owner Change0.29%
Market Cap1.89B
Analysts87
Price Target52.88 (142.01%)
Short Float %11.2%
Short Ratio10.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.64%
Min EPS beat(2)-24.53%
Max EPS beat(2)7.25%
EPS beat(4)1
Avg EPS beat(4)-6.82%
Min EPS beat(4)-24.53%
Max EPS beat(4)7.25%
EPS beat(8)5
Avg EPS beat(8)2.34%
EPS beat(12)7
Avg EPS beat(12)6.88%
EPS beat(16)8
Avg EPS beat(16)-5.96%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-89.13%
Min Revenue beat(4)-100%
Max Revenue beat(4)-56.51%
Revenue beat(8)2
Avg Revenue beat(8)-50.14%
Revenue beat(12)4
Avg Revenue beat(12)1.6%
Revenue beat(16)6
Avg Revenue beat(16)0.77%
PT rev (1m)-6.91%
PT rev (3m)-5.73%
EPS NQ rev (1m)-0.75%
EPS NQ rev (3m)-0.75%
EPS NY rev (1m)-4.33%
EPS NY rev (3m)-6.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-12.62%
Revenue NY rev (3m)-20.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 481.51
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-3.3
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0.05
BVpS13.66
TBVpS13.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.37%
ROE -15.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 147.19%
Cap/Sales 91.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.93
Quick Ratio 22.93
Altman-Z 18.77
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.54%
EPS Next Y11.16%
EPS Next 2Y5.46%
EPS Next 3Y6.92%
EPS Next 5Y21.92%
Revenue 1Y (TTM)-70.06%
Revenue growth 3Y-36.96%
Revenue growth 5YN/A
Sales Q2Q%78.43%
Revenue Next Year226.3%
Revenue Next 2Y233.35%
Revenue Next 3Y235.16%
Revenue Next 5Y177.47%
EBIT growth 1Y-88.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.81%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.32%
OCF growth 3YN/A
OCF growth 5YN/A